B. Riley Weighs in on biote’s FY2024 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD) – Equities research analysts at B. Riley upped their FY2024 earnings per share estimates for biote in a report issued on Wednesday, November 13th. B. Riley analyst J. Van. Sinderen now forecasts that the company will earn $0.74 per share for the year, up from their prior estimate of $0.50. The consensus estimate for biote’s current full-year earnings is $0.53 per share. B. Riley also issued estimates for biote’s Q4 2024 earnings at $0.06 EPS, FY2025 earnings at $0.47 EPS and FY2026 earnings at $0.70 EPS.

biote Trading Down 18.0 %

Shares of BTMD opened at $5.39 on Friday. The stock has a market cap of $292.24 million, a P/E ratio of 20.73 and a beta of 0.94. biote has a 1 year low of $3.65 and a 1 year high of $8.44. The stock’s 50-day moving average price is $5.52 and its two-hundred day moving average price is $6.28.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wasatch Advisors LP increased its stake in biote by 8.4% in the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock valued at $7,772,000 after purchasing an additional 107,792 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company’s stock valued at $4,931,000 after buying an additional 600,956 shares during the period. State Street Corp increased its position in shares of biote by 13.7% in the 3rd quarter. State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after buying an additional 57,290 shares in the last quarter. Jacobs Levy Equity Management Inc. raised its stake in biote by 24.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company’s stock worth $1,520,000 after buying an additional 54,302 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in biote by 251.8% during the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company’s stock worth $1,442,000 after acquiring an additional 138,200 shares in the last quarter. Institutional investors own 21.68% of the company’s stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.